{"name":"Royal Biologics","slug":"royal-biologics","ticker":"","exchange":"","domain":"","description":"Royal Biologics is a biotechnology company focused on developing and commercializing advanced biological products for regenerative medicine. The company's lead product, Amnio-Maxx® Dual Layer Amnion Patch, is currently marketed for use in various medical applications. Limited financial and operational data is available.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amnio-Maxx® Dual Layer Amnion Patch","genericName":"Amnio-Maxx® Dual Layer Amnion Patch","slug":"amnio-maxx-dual-layer-amnion-patch","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Amnio-Maxx® Dual Layer Amnion Patch","genericName":"Amnio-Maxx® Dual Layer Amnion Patch","slug":"amnio-maxx-dual-layer-amnion-patch","phase":"marketed","mechanism":"Wound healing and tissue regeneration","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNeDRVNllkMUNmWmpuNnpWenN6bUFnZkNaZnEwcG9BZDBvNG8zcVpSWE9BVjg3bVpBYnBMTWZXRnpmLW93SlJGX2FMNl9EcExrZENNeVV2VjMwZW1SSURBLW9XWVZnNWExSjlJaGRGUC13Qm9JdDljTy1abXc0NHR3Qi14VjU4b3Y0OUs2b3gzWnR2OHpKSGhNSkJaazJDcnlxdUhyQTRQcTc4emFaRkFsUE51OERrd3dTRFlLTXc4Qk9TX3dXRXpJdHpOTnBxM0stZjUxVmo1NlpqU1QzalNBM2I1b0tGLUUyc1dpUC04V1M2VUhoUzlF?oc=5","date":"2026-04-07","type":"regulatory","source":"PR Newswire","summary":"Royal Biologics Announces FDA Clearance for Fibrinet® PRF Wound Matrix for the Management of Cutaneous Wounds - PR Newswire","headline":"Royal Biologics Announces FDA Clearance for Fibrinet® PRF Wound Matrix for the Management of Cutaneous Wounds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9DUnJraHppdEdOZUJPalBrRnNtQy1IbmlLLWhCU2xvMC1VeENNcnRldVdMdkV0UmhQM08zc1BpYWQ3dEFsZ21iaFFuN3ZSR2Q3cnc2TWFXSW1JazVLd1lydTBsUkRwanhqVEZz?oc=5","date":"2026-03-02","type":"pipeline","source":"Labiotech.eu","summary":"17 UK biotech startups you’ll want on your radar in 2026 - Labiotech.eu","headline":"17 UK biotech startups you’ll want on your radar in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNaUUySGxwYUxXUUx3c2NLd0lEbzFFR2pkRlNja0pkZjV1bU93bmxHSHpQYkdPbVhtT012RnNVcUFzLWdudE5JNmFTeVE3TWV3bmR1ZnVUNVNlLWUyOUxYSlVlcTZueHN6ZXNUcS02V21qOElianhjc2dMQTU4MUhSSUNmZ2pydkwzcE9vWWwtVGVORXkzWXlPMkdtTFRzaG52VWVwNjM3dXI4ZDdubEhON3VNNA?oc=5","date":"2026-02-28","type":"deal","source":"Royal Gazette | Bermuda","summary":"Wilson calls on Allshores to hold off on pharmacy deal - Royal Gazette | Bermuda","headline":"Wilson calls on Allshores to hold off on pharmacy deal - Royal Gazette | Bermuda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOcTZVeFNrQ0V6eERNRm9WRUhTNTlNUTlZVUE4elI5OW9lUWhiQWluaGNmY29wSVhoS0owTlhjSHlGUUZMazFlUzI2ZlFocEhnRnQ3LUtQQ2RvMzJSU0xTcTVkR1BVN1I2MjlwY1pGb1RCRm9XQUREX1lUTmVmS0lfS3otMzF0SVRPRUllZDVwQzZrd2tEV2RULTBzeFVYN2xkZGF3?oc=5","date":"2026-02-25","type":"deal","source":"Royal Gazette | Bermuda","summary":"Insurer’s pharmacy deal draws fire from doctors - Royal Gazette | Bermuda","headline":"Insurer’s pharmacy deal draws fire from doctors - Royal Gazette | Bermuda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQbVI2bDR3dVMycVNHX29LTjVueDMzUkVLakRTSlRySUFXX3lvV0FvSHhFTmxFODlTZWRZd2sxTl9IMUoxNmxzSGZZNWVwdlpaT0tKOXI3aUVOTUlsdGpmUGljMkhMYjRJRng4b0pVWHUyY2U4Tm5HbU5qdEpPcFdTR2liUF9oTnYxVU9FLWdBTWVLcWhqMEtNU3FYWXpOYVZfbzFLX3h4NDJrQ0toT0wtMTVkUXhLZ0VDX0xCR2M2QjYtdHl6MFQ1MFhqXzZsQlNJZmZxTXJSdk5MczRCd090aFRKRXZ1cWJKSGY3akhjQmxlUkxiWjhOZHdBYUpzTHFBazRuWmFOeWEzQ0RPMzJ4UjBYTVpGc0Q2QlJMbDV1NlY5US1PaHI3ZEFUNDZkdw?oc=5","date":"2026-02-24","type":"deal","source":"PR Newswire","summary":"Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market - PR Newswire","headline":"Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdXVjNlEyakxKVmQzcXZpRnh0eGh0VDJOQXNsaW5EQnZPQ3hjZkVUSlBsc0VmTHEwcUpQSFU3LWVhOE5DU1diNmVZbWJvSFhTUThmbHZkdmdlUjdOc0ZTZkFhNFhRRHdDM3ByRnJDNWRhRjhoNTMzZFMtaXBUT0pxQWU2M05UOVY0REJJZlUzaUYxZzBIbEhyckVrX1dJeG5GS2N6LWtXVTJzMDA?oc=5","date":"2026-02-09","type":"trial","source":"Hospital Pharmacy Europe","summary":"Explore the latest in biosimilars at our new HPE Virtual Study Day - Hospital Pharmacy Europe","headline":"Explore the latest in biosimilars at our new HPE Virtual Study Day","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQX25ITmRveV8zYUlyQU5SSjZsc0pfVDFvN3E4U1lxZmtNckhfeVFJMzdGYTJyZnVlV0lpZTdNN21pb3ZKOUFmVXRRdjMwTEpqUDhPdVZ6T3d2Nlp2bEw0VnpZbVZrYXVva0RGR1R3TENsUnNNdTNhMUNjMThjeEZfRjhTbkZOeVZFR2VjVE45a3V4RTE1T2NsLXhSRzlueUt0UDY3MEZNUEdRRFVaR0s5aGVVUTBaTHV4amdNTG03NUlIMk9VWUhiZFdtd2VqQTF5QWc?oc=5","date":"2025-10-27","type":"pipeline","source":"GlobeNewswire","summary":"Wound Care Biologics Market Size Worth USD 11.22 Billion by 2034 - GlobeNewswire","headline":"Wound Care Biologics Market Size Worth USD 11.22 Billion by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPb19yV2dGdlNBTG1UNHQwRURfNm1CZUhjeE9UeFJWdEZFNU9HaE9kS0hGOTdnMW1tV29rU1ZSaFdFSk5lWnotNjlGczF2Nkg1cmdzODlUREV6ejJ6bG0zbWcwRmxqbkVHWlRtQ3ZXYjdjSVVfd0phSHJCQVczNDFDazJja1RaZExqY2xFVmVOeTl3dXBxOHpId0ZnZjZkYS05OERXRXZWYkdvYlprSlFnMUxUeW8xenJLeG9PQ3VYanFWTmd5RHdrQ1FGS3pidVNuQzlYZGJyS21BZVhWSWNrbF9tQjY?oc=5","date":"2025-02-25","type":"deal","source":"ACCESS Newswire","summary":"Royal Biologics Announces Strategic Partnership With Coldplasmatech GmbH - ACCESS Newswire","headline":"Royal Biologics Announces Strategic Partnership With Coldplasmatech GmbH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPcks1ZGRLVHVFcWFpV0NFLXU1UGRxT09NcmxuQTg3dUFQYnU1a2JXbDZCZUttTTNrbDBQUGFYRnZiTG1JaXZHOE9aSHV4SS01czUwMUl2eVVuSDdtbWJ1OTRhb0tpOENpRXJUSVJlRmZ1TGdVRHdrel9hYVVSVUxNMmdIQmxnWm1hQVF2WV9pRnZITlV5UnJHMzI5UWFUeXpzdGVCNlZlb0tuLW1zNmZ1aGN0R3ZnQ0k4azh4UHMwRDU1QzdXQjNkODJacXZjcEhqd3NKYmlGNlVxODF3UzFLNURaVHJYRE9wN2FpNVJrTTVUa0xndWFGaTc5dl9faDF6WmNZYWJNaUk?oc=5","date":"2023-06-13","type":"pipeline","source":"Proactive financial news","summary":"Small cap snapshot: Royal Helium, MustGrow Biologics, Tocvan Ventures, Tiziana Life Sciences, G Mining Ventures... - Proactive financial news","headline":"Small cap snapshot: Royal Helium, MustGrow Biologics, Tocvan Ventures, Tiziana Life Sciences, G Mining Ventures...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQN0kxWWJtU1Jmc3RDWENXZGlLb3RNU1lDQzhMV0FQdkNIRUk4SGREQ2ptU2ltYXpuRGpNeV9yUThlWWN3MHF1cGJLeHl5RE9Od3UtUG16d2V0ZzZMcmVhcWthNklBRkJnQUNQMVh4cXA5SXJCNTRfRlRERFhLV2FiU2FCQkg5dWZaWV9GWmtWSmtDS25Gb2ZBbFlObk1yTmNJVHlXenFsYVhiWUFVY3R6Uk9vQXlPdFBLX1dPTEQ0MkpIbWh0TVRXag?oc=5","date":"2022-07-08","type":"patent","source":"pharmaceutical-journal.com","summary":"Initiating biologics and biosimilars in practice: approach and consultation guidance - pharmaceutical-journal.com","headline":"Initiating biologics and biosimilars in practice: approach and consultation guidance - pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQRHIwT3VBVW90UDREdUo1eEFlenpXRUktdkVhOWgyYXQ1b19pMHR2SkVzalYzT2NTRmhTUno2eHhva1lfWFVRSUwwdkozSHBSSUwtMTBwQWVEaVo5SjRfcnFEVFhxY3A4VVU2RWUwX0syNmdWeXllemtzSmd3UG5vby1ieXlZWVpkY3llV0hOb05uYTdmT2lUcmZ1bFdlSDJsZkc0d1djWFVVajUybWlRTG9IZzg2TjhkTkdiNFFxZ0lnc2pvTUllaHU2S2Y0N21NSHRpS2VfMmE0dw?oc=5","date":"2022-04-26","type":"pipeline","source":"BioSpace","summary":"Royal Biologics Announces U.S. Commercial Launch of Advanced-Cell™, an Advanced Bone Grafting and Fusion Convenience Kit - BioSpace","headline":"Royal Biologics Announces U.S. Commercial Launch of Advanced-Cell™, an Advanced Bone Grafting and Fusion Convenience Kit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOd2Rma2hXX3VxMW5HMWZSYWxmc1hsakNkbUxUYzAxcV9ndENkTXRDWm9oN2oyTUNQblliX0U2eUdvSTdyWnc0emR3ZUM0SHdNRmtjblk1VjExcWlRbW52cFozaEcwNXkwekxkUE1ZOUs1M3RfQldvT0lreHdVeXhoUjA3TG1WWWwtUlNHOWVFc3BjdV9zRjVUVkcxZ0M?oc=5","date":"2021-09-08","type":"regulatory","source":"BioSpace","summary":"Royal Biologics Announces FDA Approval of the Maxx™ Concentration System. - BioSpace","headline":"Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}